Anatomic Pathology Market Analysis

Type (Services, Consumables, Instruments); Subdivision (Histopathology, Cytopathology)

The global anatomic pathology market is segmented and analyzed for demand and supply by type into services, consumables, and instruments. Amongst these segments, the services segment held the largest share, backed by the growing number of breast cancers along with the surge in the number of biopsies done worldwide. For instance, over 17 720 biopsies were recommended and performed, in between January 2019 to September 2020 in the United States.

Our in-depth analysis of the global market includes the following segments:

By Type	Services – 48.12% Consumables – 40.70% Instruments – 11.18%
By Subdivision	Histopathology Cytopathology
By Product Type	Recombinant Non-Glycosylated Proteins - 63% Recombinant Glycosylated Proteins - 32% Recombinant Peptides - 5%
By Application	Disease Diagnosis Drug Discovery & Development
By End-User	Hospitals Diagnostic Laboratories, Research & Academic Laboratories

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of anatomic pathology is evaluated at USD 41.1 billion.

The anatomic pathology market size was valued at USD 38.48 billion in 2024 and is anticipated to exceed USD 108.01 billion by the end of 2037, registering over 8.4% CAGR during the forecast period i.e., between 2025-2037. Increasing number of laboratory tests as well as biopsies performed along with rising cases of cancer, kidney diseases and others will propel the market growth.

North America industry will hold a share of 38% by 2037, backed by presence of a strong healthcare network in the region.

The major players in the market include PHC Holdings Corporation, Indica Labs, Inc., F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Sakura Finetek USA, Inc., Cardinal Health, Inc., BioGenex, NeoGenomics Laboratories, Inc., Agilent Technologies, Inc.

Anatomic Pathology Market Analysis